Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the lithium giant exploded to $145.38. This morning, it’s up another $4.15 and…
Shares of Novo Nordisk A/S (NYSE: NVO | NVO Price Prediction) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share…
If the headline yield today is not something you’re concerned with, and you pay more attention to how fast a yield can grow, then it’s worth buying dividend stocks you can forget…
In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were not the only notable purchases though.
The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over…
The U.S. stock market has delivered impressive gains for over a decade, but warning signs of a potential downturn are mounting. Inflation remains sticky, interest rates hover at levels that could squeeze…
The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO | NVO Price Prediction) and Eli…
Starting today, the U.S. imposed 100% tariffs on imports of branded or patented pharmaceutical products that President Trump announced last week. This sweeping measure targets foreign-made drugs to push manufacturers toward U.S.…
Insider buying is one of the few market signals that does not hide behind algorithms or price targets. When a director pulls out a personal checkbook and adds to his stake while…
Healthcare investing has felt like walking through quicksand this year. One moment, the sector looks ready to spring forward on breakthrough drugs and aging demographics, the next, it is yanked back by…
A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway success of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic and Wegovy. These injectable…
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its blockbuster…
Live Updates Tuesday Wrap-up4:12pm ETThe Vanguard S&P 500 ETF closed at 588.15 Tuesday, down 0.5%. Softbank Rides to Intel's Rescue12:10pm ET“Great minds think alike,” goes the old saying, and today, one of…
Live Updates Monday Wrap-up4:11pm ETThe Vanguard S&P 500 ETF closed at 591.36 Monday, down 0.04%. BREAKING NEWS: INTEL12:32pm ETBloomberg just reported — literal seconds ago — that the Trump Administration is discussing…
Weighing the Options The introduction of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic revolutionized the fight against obesity, shifting the narrative from lifestyle interventions to pharmacological solutions. Glucagon-like peptide-1 (GLP-1) receptor…
